Form 8-K - Current report:
SEC Accession No. 0001193125-25-045605
Filing Date
2025-03-04
Accepted
2025-03-04 16:16:10
Documents
16
Period of Report
2025-02-28
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 5.07: Submission of Matters to a Vote of Security Holders
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d892218d8k.htm   iXBRL 8-K 47949
2 EX-10.1 d892218dex101.htm EX-10.1 127656
3 EX-10.2 d892218dex102.htm EX-10.2 95598
4 EX-99.1 d892218dex991.htm EX-99.1 9231
  Complete submission text file 0001193125-25-045605.txt   462657

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA aadi-20250228.xsd EX-101.SCH 2841
6 XBRL TAXONOMY EXTENSION LABEL LINKBASE aadi-20250228_lab.xml EX-101.LAB 17994
7 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE aadi-20250228_pre.xml EX-101.PRE 11255
18 EXTRACTED XBRL INSTANCE DOCUMENT d892218d8k_htm.xml XML 3650
Mailing Address 17383 SUNSET AVENUE SUITE A250 PACIFIC PALISADES CA 90272
Business Address 17383 SUNSET AVENUE SUITE A250 PACIFIC PALISADES CA 90272 424-473-8055
Aadi Bioscience, Inc. (Filer) CIK: 0001422142 (see all company filings)

EIN.: 611547850 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38560 | Film No.: 25704636
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)